Proteomics International: Secures licence for oesophageal cancer biomarkers

Proteomics International Secures licence for oesophageal cancer biomarkers

  • Proteomics International Laboratories (PIQ) secures a worldwide licence for oesophageal cancer biomarkers
  • The licence agreement to commercialise biomarkers that test for oesophageal adenocarcinoma has been signed with the QIMR Berghofer Medical Research Institute
  • Under the contract, QIMR’s intellectual property in the biomarkers will become licensed exclusively to Prote omics, which the company will use to develop and commercialise a simple blood test for the cancer
  • The company says it will now undertake additional studies to confirm the diagnostic performance of the potential new blood test, which will take approximately six months
  • The company International is up 2.56 per cent, trading at 80 cents at 2:03 pm AEST
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Lloyds Strengthens AI Strategy After Assessing Financial Value of Deployments

The bank plans to enhance its artificial intelligence capabilities further.Highlights: Lloyds assesses the financial value of its AI...

Santander Tightens Operations with Closure of 44 More Branches

The bank continues its restructuring as customer preferences shift to digital banking.Highlights: Santander is closing 44 more branches...

Stablecoin Bank Kontigo Suffers Cyber Attack, Disrupting Operations

The cyber incident raises concerns about security in fintech.Highlights: Kontigo, a prominent stablecoin bank, experienced a cyber attack.The...

Universal Launches UAE’s First Central Bank Registered Stablecoin

The new digital currency aims to enhance financial transactions in the UAE.Highlights: Universal launched the UAE's first Central...